Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis D
Biotech
Vir links up with Norgine in €550M hepatitis D licensing deal
Norgine secured an exclusive license to commercialize Vir Biotechnology's hepatitis D prospect in Europe, Australia and New Zealand.
Zoey Becker
Dec 17, 2025 12:50pm
Mirum nets Bluejay and its ph. 3-stage hepatitis drug for $620M
Dec 8, 2025 9:45am
Vir won't advance potential hep B 'cure' without a partner
Feb 27, 2025 11:37am
Vir gains 3 T-cell engagers from Sanofi, lays off 25% of staff
Aug 2, 2024 6:12am
Vir keeps pressure on Gilead with midphase hepatitis D data
Jun 5, 2024 8:52am
